EyePoint to cut workforce by half after experimental drug fails second late-stage trial

EyePoint on Monday said it would cut about 53% of its workforce and stop ​studies of its experimental eye drug for ‌an age-related vision disease after it failed a second…

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.reuters.com)